Day: May 10, 2022

CALGARY, Alberta, May 10, 2022 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces first quarter results for the period ended March 31, 2022. Operating and Financial Highlights  Three Months Ended March 31 Three Months Ended December 31FINANCIAL ($ millions, except as noted) 2022   2021   Change 2021   ChangeFunds from operations 71.9   32.4   122 % 68.7   5 %Funds from operations per share, basic ($) (1) 0.48   0.25   92 % 0.46   4 %Acquisitions and related expenditures 1.3   79.8   nm   67.9   nm  Dividends paid per share ($) (2) 0.18   0.06   200 % 0.16   13 %Payout ratio (%) (3) 38 % 24 % 14 % 35 % 3 %Net debt 62.6   64.8   (3 %) 101.2   (38 %)OPERATING          Total production (boe/d) (4) 13,676   10,944   25 % 14,005   (2 %)Oil and NGL (%) 60 % 54 % 6 % 59 % 1 %Petroleum...

TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year Cash runway expected into at least 2026 IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for eye diseases, today announced financial results for the first quarter ended March 31, 2022, and recent business achievements. “In the first quarter, we took important steps towards becoming a leading eye care pharmaceutical company. We reported strong and consistent Saturn-2 data, further validating the safety and efficacy of TP-03 and positioning it as the definitive standard of care for millions of patients who suffer from Demodex...

– STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 – – New Drug Application (NDA) submission anticipated in Q1 2023 – – $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, provides runway into second half of 2023 – SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the first quarter of 2022 and summarized recent business highlights. “We are pleased to report continued progress during the first quarter as we advance toward...

InteliSwab® revenue of $22.1 million in Q1, up 50% sequentially with significant scaling in production Non-COVID molecular kits increase 42% year-over-year demonstrating continued strong growth Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, Pa., May 10, 2022 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended March 31, 2022. “We made significant progress in the quarter scaling InteliSwab® production and improving the efficiency of our manufacturing process as we look to drive profitable growth,” said OraSure Interim President and CEO Nancy J. Gagliano, M.D., MBA. “Excluding COVID-19 products,...

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months ended March 31, 2022 and provided an update on key initiatives. Business UpdateTricida continued to execute on the conduct of the VALOR-CKD renal outcomes clinical trial. Enrollment of patients in the VALOR-CKD trial was completed at the end of 2021 with 1,480 subjects randomized. As of May 9, 2022, randomized subjects had an average treatment duration of approximately 25 months, and the trial had accrued 233 subjects with positively adjudicated primary endpoint events, defined as renal death, end-stage renal disease (ESRD), or greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR).Upcoming MilestoneTricida previously...

Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic CAR T and in vivo fusogen CAR T SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the first quarter 2022. “In the first quarter, we made significant progress in moving toward clinical trials for programs across our multiple platforms including the ex vivo hypoimmune allogeneic CAR T (SC291) and in vivo fusogen CAR T (SG295) programs, and we remain on track to file INDs for both of these programs this year,” said Steve Harr, Sana’s President and Chief Executive Officer....

CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Results Summary:Net revenue of $98.1 million for the first quarter of 2022, a decrease of 4% (an increase of 1% on an adjusted basis1) compared to net revenue of $102.6 million for the first quarter of 2021. Net revenue for the first quarter of 2022 consists of:Net revenue from Advanced Wound Care products of $91.0 million, an increase of 0.3% from the first quarter of 2021. Net revenue from Surgical & Sports Medicine products of $7.2...

SAN FRANCISCO, May 10, 2022 (GLOBE NEWSWIRE) — Metromile, Inc. (“Metromile”) (NASDAQ: MILE, MILEW), a leading digital insurance platform and pay-per-mile auto insurer, today announced financial results for the first quarter 2022 on its website. The results are accessible on Metromile’s investor relations website at ir.metromile.com.      Due to the pending transaction with Lemonade announced on November 8, 2021, the Company will not host a conference call in conjunction with its first quarter 2022 earnings release. Please visit the Investor Relations section of the Company’s website at ir.metromile.com for the latest releases and information. About Metromile Metromile (NASDAQ: MILE, MILEW) is a leading digital insurance platform in the United States. With data science as its foundation, Metromile offers real-time, personalized...

— Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 — SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022. “We made significant headway in the transfer of mivavotinib and sapanisertib materials to Calithera during the first quarter and are well into site start-up activities. We are on track to begin enrolling patients in both mivavotinib and sapanisertib trials in the second quarter of 2022 and expect to share data from these studies by the first quarter of 2023,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “We are also excited about our preclinical...